title: A novel topical nano-propranolol for treatment of infantile hemangiomas.
abstract: Topical propranolol has been used for the therapy of superficial infantile hemangiomas (IH). A retrospective investigation was conducted in 50 patients to evaluate the clinical effect of a new type of topical nano-propranolol-dispersed hydrogel. Participants were treated 3 times per day for 2 weeks to 11 months. 68% of patients were female and 12% had received other treatments before therapy. The nano-propranolol 0.5% hydrogel was initiated at a mean age of 5.010 months and for a mean duration of 3.610 months. The response rate was 86%. No recurrence and rebound growth occurred after withdrawal of hydrogel. Slight side effects (application site itching, erosion and crusting) were observed in only 2 cases. All the local irritations were evaluated as mild and were tolerated without discontinuing the medication. We suggest that topical nano-propranolol hydrogel could be an alternative option for the treatment of uncomplicated superficial IH with satisfactory tolerability and optimal effectiveness.
  
  
  BACKGROUND
  The current recommended treatment for infantile hemangiomas is oral propranolol. Nonetheless, a small proportion of patients will have systemic side effects. In this article, the authors developed topical nano-propranolol hydrogel and tested this on clinical patients and found favorable response.
authors: Department of Oromaxillofacial Head and Neck Oncology, Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Department of Oral and Maxillofacial Surgery, Qingdao Municipal Hospital, Shandong, China.
authors: Zheng Gang
authors: ZG
authors: Chen
authors: Department of Oromaxillofacial Head and Neck Oncology, Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: davidzhengjw@sjtu.edu.cn.
authors: Jia Wei
authors: JW
authors: Zheng
authors: School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
authors: Ming Lu
authors: ML
authors: Yuan
authors: Department of Oromaxillofacial Head and Neck Oncology, Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
authors: Ling
authors: L
authors: Zhang
authors: School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China. Electronic address: yuanweien@126.com.
authors: Wei En
authors: WE
authors: Yuan
mesh_terms: D000287:Administration, Topical; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006391:Hemangioma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D020100:Hydrogels / Q000737:chemistry; D007223:Infant; D008297:Male; D049329:Nanostructures / Q000737:chemistry; D014677:Pharmaceutical Vehicles / Q000737:chemistry; D011433:Propranolol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000319:Adrenergic beta-Antagonists; D020100:Hydrogels; D014677:Pharmaceutical Vehicles; D011433:Propranolol
keywords: Beta blocker; Infantile hemangioma; Propranolol; Topical therapy